Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review

BioDrugs

Volumn 32, Issue 1, 2018, Pages 27-52

  McKinnon, Ross A ^a   Cook, Matthew ^b   Liauw, Winston ^c,d   Marabani, Mona ^e   Marschner, Ian C ^f,g   Packer, Nicolle H ^f,h   Prins, Johannes B ⁱ  

^a FLINDERS UNIVERSITY   (Australia)

^b Australian National University   (Australia)

^c ST GEORGE HOSPITAL   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e Canterbury Hospital   (Australia)

^f MACQUARIE UNIVERSITY   (Australia)

^g UNIVERSITY OF SYDNEY   (Australia)

^h GRIFFITH UNIVERSITY   (Australia)

ⁱ UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; DRUG ANTIBODY;

COCHRANE LIBRARY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; EFFICACY PARAMETERS; EMBASE; FOLLOW UP; HUMAN; IMMUNOGENICITY; MEDLINE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

BIOSIMILAR PHARMACEUTICALS; HUMANS;

EID: 85040669431     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-017-0256-z     Document Type: Review

References (134)

1. Reusch D, Tejada ML. Fc glycans of therapeutic antibodies as critical quality attributes. Glycobiology. 2015;25(12):1325–34.
2. Ramanan S, Grampp G. Drift, evolution, and divergence in biologics and biosimilars manufacturing. BioDrugs. 2014;28(4):363–72.
3. US Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. 2015. http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf. Accessed 5 Sep 2016.
4. European Medicines Agency (EMA). Guideline on similar biological medicinal products. 2014. http://www.ema.europaeu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf. Accessed 5 Sep 2015.
5. Australian Therapeutic Goods Administration (TGA). Regulation of biosimilar medicines (Version 2.0, December 2015). https://www.tga.gov.au/sites/default/files/evaluation-biosimilars-151217_0.pdf. Accessed 5 Sep 2016.
6. US Food and Drug Administration (FDA). Guidance for industry: immunogenicity assessment for therapeutic protein products. 2014. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm338856.pdf. Accessed 6 Sep 2016.
7. Australian Government Department of Health. Biosimilar medicines—factsheet for healthcare professionals. 2016. http://www.pbs.gov.au/publication/factsheets/biosimilars/biosimilars-factsheet-healthcare-professionals.pdf. Accessed 8 Sep 2016.
8. Australian Pharmaceutical Benefits Scheme (PBS) Pharmaceutical Benefit Advisory Committee (PBAC). PBAC special meeting minutes. 2015. http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/2015-04/2015-04-biosimilars.pdf. Accessed 8 Sep 2016.
9. US Food and Drug Administration (FDA). Biosimilars: questions and answers regarding implementation of the biologics price competition and innovation act 2009: guidance for industry. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm444661.pdf. Accessed 8 Sep 2016.
10. European Medicines Agency (EMA). Biosimilars in the EU: information guide for healthcare professionals. 2017. http://www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2017/05/WC500226648.pdf. Accessed 5 Oct 2017.
11. Australian Therapeutic Goods Administration (TGA). Consultation: nomenclature of biological medicines (Version 1.0, July 2017). https://www.tga.gov.au/sites/default/files/consultation-nomenclature-biological-medicines.pdf. Accessed 24 Oct 2017.
12. Papamichael K, Van Stappen T, Jairath V, Gecse K, Khanna R, D’Haens G, et al. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases. Aliment Pharmacol Ther. 2015;42(10):1158–69.
13. Dörner T, Strand V, Cornes P, Goncalves J, Gulacsi L, Kay J, et al. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis. 2016;75(6):974–82.
14. Heinemann L, Home PD, Hompesch M. Biosimilar insulins: guidance for data interpretation by clinicians and users. Diabetes Obes Metab. 2015;17(10):911–8.
15. European Commission. Consensus information paper: what you need to know about biosimilar medicinal products. 2013. http://ec.europa.eu/DocsRoom/documents/8242. Accessed 8 Sep 2016.
16. Declerck P, Endrenyi L, Chow SC. Interchangeability, switchability and substitution of biosimilar products. In: Endrenyi LDPJ, Chow SC, editors. Biosimilar drug product development. London and New York: CRC Press/Taylor & Francis; 2017.
17. Kurki P, van Aerts L, Wolff-Holz E, Giezen T, Skibeli V, Weise M. Interchangeability of biosimilars: a European perspective. BioDrugs. 2017;31(2):83–91.
18. US Food and Drug Administration. Therapeutic biologic applications (BLA): information for industry (biosimilars). 2016. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm241720.htm. Accessed 5 Sep 2016.
19. US Food and Drug Administration. Considerations in demonstrating interchangeability with a reference product: guidance for industry (draft). 2017. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM537135.pdf. Accessed 25 Jan 2017.
20. Allens Linklaters. Costs before caution—Australia’s unique approach to the interchangeability of biosimilars. 2016. http://www.allens.com.au/pubs/pdf/healthcare/BiosimilarsWhitePaper-CostsbeforeCaution.pdf. Accessed 8 Sep 2016.
21. Kay J, Isaacs JD. Clinical trials of biosimilars should become more similar. Ann Rheum Dis. 2017;76(1):4–6.
22. American College of Rheumatology (ACR). Position statement: biosimilars. 2016. http://www.rheumatology.org/Portals/0/Files/Biosimilars-Position-Statement.pdf. Accessed 11 Aug 2016.
23. Australian Diabetes Society (ADS) and Diabetes Australia and Australian Diabetes Educators Association (ADEA). 2015. Position statement: use of ‘biosimilar’ insulins for diabetes. https://diabetessociety.com.au/documents/BiosimilarSubstitutionPositionStatementDAADSADEATBFV20150911.pdf. Accessed 5 Sep 2016.
24. American Society of Clinical Oncology. ASCO policy brief: biosimilars. 2015. https://www.asco.org/sites/new-wwwascoorg/files/content-files/advocacy-and-policy/documents/2013_biosilimars%20New.pdf. Accessed 5 Sep 2016.
25. National Rheumatoid Arthritis Society (NRAS). NRAS position paper on biosimilars—revised June 2016. http://www.nras.org.uk/data/files/About%20RA/How%20is%20RA%20managed/NRAS%20Biosimilars%20Position%20Paper%20Final.pdf. Accessed 5 Sep 2016.
26. American Academy of Dermatology. Position paper on generic therapeutic & biosimilar substitution. 2013. https://www.aad.org/Forms/Policies/Uploads/PS/PS-Generic%20Therapeutic%20and%20%20Biosimilar%20Substitution.pdf. Accessed 6 Oct 2016.
27. Tabernero J, Vyas M, Giuliani R, Arnold D, Cardoso F, Casali PG, et al. Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. ESMO Open. 2017;1(6):e000142.
28. Annese V, Vecchi M. Use of biosimilars in inflammatory bowel disease: statements of the Italian Group for Inflammatory Bowel Disease. Dig Liver Dis. 2014;46(11):963–8.
29. Fiorino G, Girolomoni G, Lapadula G, Orlando A, Danese S, Olivieri I. The use of biosimilars in immune-mediated disease: a joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. Autoimmun Rev. 2014;13(7):751–5.
30. Abad Hernández MA, Andreu JL, Caracuel Ruiz MA, Belmonte Serrano MA, Diaz-Gonzalez F, Moreno Muelas JV. Position paper from the Spanish Society of Rheumatology on biosimilar drugs. Reumatol Clin. 2015;11(5):269–78.
31. Klein AV, Wang J, Bedford P. Subsequent entry biologics (biosimilars) in Canada: approaches to interchangeability and the extrapolation of indications and uses. GaBi J. 2014;3(3):150–4.
32. Devlin SM, Bressler B, Bernstein CN, Fedorak RN, Bitton A, Singh H, et al. Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics. Can J Gastroenterol. 2013;27(10):567–71.
33. Gastroenterological Society of Australia (GESA) and Australian Inflammatory Bowel Disease Association (AIBDA). GESA-AIBDA position on biosimilars substitution. 2015. http://www.gesa.org.au/files/editor_upload/File/NEWS/Position%20on%20Biosimilars%20GESA_AIBDA.pdf. Accessed 6 Oct 2016.
34. Arthritis Australia. Biosimilars and biologics: what you need to know. 2015. http://arthritisaustralia.com.au/indexphp/63-news/301-biosimilars-and-biologics-what-you-need-to-know.html. Accessed 6 Oct 2016.
35. Australian Rheumatology Association (ARA). ARA position on the introduction of biosimilars for the treatment of rheumatic diseases. 2016. http://rheumatology.org.au/rheumatologists/documents/20161124%20ARA%20position%20statement%20biosimilars%20Nov%2016%20final.pdf. Accessed 13 Dec 2016.
36. Danese S, Gomollon F. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis. 2013;7(7):586–9.
37. European League Against Rheumatism (EULAR). Biosimilars: what do patients need to consider? 2015. http://www.eular.org/myUploadData/files/Biosimilars_2015.pdf. Accessed 5 Sep 2016.
38. Pharmaceutical Society of Australia. Biosimilar medicines: position statement. 2015. http://www.psa.org.au/downloads/ent/uploads/filebase/policies/biosimilar-medicines-position-statement.pdf. Accessed 6 Oct 2016.
39. The Pharmacy Guild of Australia. Policy: biosimilar medicines. 2015. https://www.guild.org.au/docs/default-source/public-documents/issues-and-resources/Policy-and-Position-Statements/20151026-guild-biosimilar-medicines.pdf?sfvrsn=0. Accessed 6 Oct 2016.
40. Hausberger A, Lamanna WC, Hartinger M, Seidl A, Toll H, Holzmann J. Identification of low-level product-related variants in filgrastim products presently available in highly regulated markets. BioDrugs. 2016;30(3):233–42.
41. Mastrangeli R, Satwekar A, Cutillo F, Ciampolillo C, Palinsky W, Longobardi S. In-vivo biological activity and glycosylation analysis of a biosimilar recombinant human follicle-stimulating hormone product (Bemfola) compared with its reference medicinal product (GONAL-f). PLoS One. 2017;12(9):e0184139.
42. Bracewell DG, Francis R, Smales CM. The future of host cell protein (HCP) identification during process development and manufacturing linked to a risk-based management for their control. Biotechnol Bioeng. 2015;112(9):1727–37.
43. Abdalla A, Byrne N, Conway R, Walsh T, Mannion G, Hanly M, et al. Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product. Open Access Rheumatol. 2017;9:29–35.
44. Ala K, Avery P, Wilson R, Prowse A, Shutt J, Jupp J, et al. Early experience with biosimilar infliximab at a district general hospital for an entire Crohns disease patient cohort switch from Remicade to Inflectra. Gut. 2016;65:A81 (abstract).
45. Arguelles-Arias F, Guerra Veloz MF, Perea Amarillo R, Vilches-Arenas A, Castro Laria L, Maldonado Perez B, et al. Effectiveness and safety of CT-P13 (biosimilar infliximab) in patients with inflammatory bowel disease in real life at 6 months. Dig Dis Sci. 2017;62(5):1305–12.
46. Bennett KJ, Heap GA, Hawkins S, Ahmad T. Prospective evaluation of the safety and efficacy of switching stable patients with inflammatory bowel disease from Remicade™ to biosimilar infliximab (IFX). Gut. 2016;65:A146 (abstract).
47. Benucci M, Gobbi FL, Bandinelli F, Damiani A, Infantino M, Grossi V, et al. Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study. Immunol Res. 2017;65(1):419–22.
48. ® is well tolerated and feasible: a prospective, open-label study. J Crohns Colitis. 2017;11(3):297–304.
49. Dapavo P, Vujic I, Fierro MT, Quaglino P, Sanlorenzo M. The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75(4):736–9.
50. Fiorino G, Manetti N, Armuzzi A, Orlando A, Variola A, Bonovas S, et al. The PROSIT-BIO cohort: a prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar. Inflamm Bowel Dis. 2017;23(2):233–43.
51. Gentileschi S, Barreca C, Bellisai F, Biasi G, Brizi MG, De Stefano R, et al. Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseases. Response to: Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15:1677–1683. Expert Opin Biol Ther. 2016:1–2.
52. Glintborg B, Sorensen IJ, Loft AG, Lindegaard H, Linauskas A, Hendricks O, et al. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis. 2017;76:1426–31.
53. Jorgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389(10086):2304–16.
54. Jung YS, Park DI, Kim YH, Lee JH, Seo PJ, Cheon JH, et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol. 2015;30(12):1705–12.
55. Kay J, Chopra A, Lassen C, Shneyer L, Wyand M. BOW015, a biosimilar infliximab: disease activity and disability outcomes from a phase 3 active comparator study in patients with active rheumatoid arthritis on stable methotrexate doses. Ann Rheum Dis. 2015;74(Suppl 2):462–3 (abstract).
56. Kay J, Lassen C, Trokan L, Wyand M. Safety profile of BOW015, a biosimilar infliximab, in healthy subjects and patients with active rheumatoid arthritis. Ann Rheum Dis. 2015;74(Suppl 2):706 (abstract).
57. Kolar M, Duricova D, Bortlik M, Hruba V, Machkova N, Mitrova K, et al. Infliximab biosimilar (Remsima) in therapy of inflammatory bowel diseases patients: experience from one tertiary inflammatory bowel diseases centre. Dig Dis. 2017;35(1–2):91–100.
58. Nikiphorou E, Kautiainen H, Hannonen P, Asikainen J, Kokko A, Rannio T, et al. Clinical effectiveness of CT-P13 (infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15(12):1677–83.
59. Park SH, Kim YH, Lee JH, Kwon HJ, Lee SH, Park DI, et al. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Expert Rev Gastroenterol Hepatol. 2015;9(Suppl 1):35–44.
60. Park W, Suh CH, Shim SC, Molina FFC, Jeka S, Medina-Rodriguez FG, et al. Efficacy and safety of switching from innovator rituximab to biosimilar CT-P10 compared with continued treatment with CT-P10: results of a 56-week open-label study in patients with rheumatoid arthritis. BioDrugs. 2017;31(4):369–77.
61. Park W, Yoo DH, Miranda P, Brzosko M, Wiland P, Gutierrez-Urena S, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis. 2017;76:346–54.
62. Rahmany S, Cotton S, Garnish S, Brown M, Saich R, Lloyd D, et al. In patients with IBD switching from originator infliximab (Remicade) to biosimilar infliximab (CT-P13) is safe and effective. Gut. 2016;65:A89 (abstract).
63. Razanskaite V, Bettey M, Downey L, Wright J, Callaghan J, Rush M, et al. Biosimilar infliximab in inflammatory bowel disease: outcomes of a managed switching programme. J Crohns Colitis. 2017;11(6):690–6.
64. ®. Ann Rheum Dis. 2016;75(Suppl 2):1006 (abstract).
65. Sheppard M, Hadavi S, Hayes F, Kent J, Dasgupta B. Preliminary data on the introduction of the infliximab biosimilar (CT-P13) to a real world cohort of rheumatology patients. Ann Rheum Dis. 2016;75(Suppl 2):1011 (abstract).
66. Sieczkowska J, Jarzebicka D, Banaszkiewicz A, Plocek A, Gawronska A, Toporowska-Kowalska E, et al. Switching between infliximab originator and biosimilar in paediatric patients with inflammatory bowel disease. Preliminary observations. J Crohns Colitis. 2016;10(2):127–32.
67. Schmitz EMH, Benoy-De Keuster S, Meier AJL, Scharnhorst V, Traksel RAM, Broeren MAC, et al. Therapeutic drug monitoring (TDM) as a tool in the switch from infliximab innovator to biosimilar in rheumatic patients: results of a 12-month observational prospective cohort study. Clin Rheumatol. 2017;36(9):2129–34.
68. ® to the biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study. J Crohns Colitis. 2016;10:1287–93.
69. Smolen JS, Choe J-Y, Prodanovic N, Niebrzydowski J, Staykov I, Dokoupilova E, et al. Comparable safety and immunogenicity and sustained efficacy after transition to SB2 (an infliximab biosimilar) vs ongoing infliximab reference product in patients with rheumatoid arthritis: results of phase III transition study. Ann Rheum Dis. 2016;75(Suppl 2):488 (abstract).
70. Tanaka Y, Yamanaka H, Takeuchi T, Inoue M, Saito K, Saeki Y, et al. Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab. Mod Rheumatol. 2017;27(2):237–45.
71. Tweehuysen L, Van Den Bemt BJF, Van Ingen IL, De Jong AJL, Van Der Laan WH, Van Den Hoogen FHJ, et al. Clinical and immunogenicity outcomes after switching treatment from innovator infliximab to biosimilar infliximab in rheumatic diseases in daily clinical practice. Arthritis Rheumatol. 2016;68:821–3 (abstract).
72. Yazici Y, Xie L, Ogbomo A, Parenti D, Goyal K, Teeple A, et al. A descriptive analysis of real-world treatment patterns in a Turkish rheumatology population that continued innovator infliximab (Remicade) therapy or switched to biosimilar infliximab. Arthritis Rheumatol. 2016;68:2903–6 (abstract).
73. Yoo DH, Prodanovic N, Jaworski J, Miranda P, Ramiterre E, Lanzon A, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis. 2017;76:355–63.
74. Haag-Weber M, Vetter A, Thyroff-Friesinger U. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. Clin Nephrol. 2009;72(5):380–90.
75. Harzallah A, Zouaghi K, Dridi A, Boubaker K, Beji S, Ayari M, et al. Therapeutic efficacy of a biosimilar epoetin alfa in hemodialysis patients. Saudi J Kidney Dis Transpl. 2015;26(1):78–82.
76. Hörbrand F, Bramlage P, Fischaleck J, Hasford J, Brunkhorst R. A population-based study comparing biosimilar versus originator erythropoiesis-stimulating agent consumption in 6,117 patients with renal anaemia. Eur J Clin Pharmacol. 2013;69(4):929–36.
77. Lopez MJ, del García Busto N, Carrascosa O, Mejía L, Antonino G, De La Vega I, et al. Biosimilar epoetin zeta in the treatment of chemotherapy-induced anaemia. Eur J Hosp Pharm. 2014;21:A38–9.
78. Minutolo R, Borzumati M, Sposini S, Abaterusso C, Carraro G, Santoboni A, et al. Dosing penalty of erythropoiesis-stimulating agents after switching from originator to biosimilar preparations in stable hemodialysis patients. Am J Kidney Dis. 2016;68(1):170–2.
79. Morosetti M, Dominijanni S, Calzona AB, Zappalà L, Nicolais R, Di Turi R. Switch to biosimilars in hemodialysis patients: efficacy, safety and cost analysis in a single centre. Ricerca e Pratica. 2017;33(1):5–12.
80. Ohta S, Yasuno N, Inomoto Y, Matsuda K, Nakagawa Y, Sasagawa I, et al. Efficacy of once or twice weekly administration of epoetin kappa in patients receiving hemodialysis: a retrospective study. Exp Ther Med. 2014;7(1):27–30.
81. Wiecek A, Ahmed I, Scigalla P, Koytchev R. Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: posthoc analysis. Adv Ther. 2010;27(12):941–52.
82. Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Curr Med Res Opin. 2008;24(3):625–37.
83. Balili CAV, Mendoza ESR, Mercado-Asis LB. Shifting to biosimilar insulin preparation: impact on glycemic control and cost. Endocrine Reviews. 2015;36:abstract THR-659.
84. Hadjiyianni I, Dahl D, Lacaya LB, Pollom RK, Chang CL, Ilag LL. Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine. Diabetes Obes Metab. 2016;18(4):425–9.
85. Ilag LL, Deeg MA, Costigan T, Hollander P, Blevins TC, Edelman SV, et al. Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus(R) insulin glargine in patients with type 1 or type 2 diabetes mellitus. Diabetes Obes Metab. 2016;18(2):159–68.
86. Rosenstock J, Hollander P, Bhargava A, Ilag LL, Pollom RK, Zielonka JS, et al. Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus(R)) in patients with type 2 diabetes who were insulin-naive or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study). Diabetes Obes Metab. 2015;17(8):734–41.
87. Segal D, Tupy D, Distiller L. The Biosulin equivalence in standard therapy (BEST) study—a multicentre, open-label, non-randomised, interventional, observational study in subjects using Biosulin 30/70 for the treatment of insulin-dependent type 1 and type 2 diabetes mellitus. S Afr Med J. 2013;103(7):458–60.
88. Flodmark CE, Lilja K, Woehling H, Jarvholm K. Switching from originator to biosimilar human growth hormone using dialogue teamwork: single-center experience from Sweden. Biol Ther. 2013;3:35–43.
89. ®: an experience of a single paediatric centre in Spain. Horm Res Paediatr. 2014;82:414 (abstract).
90. ® from other recombinant human growth hormone therapies: a retrospective study in an integrated healthcare system. Biol Ther. 2014;4(1–2):27–39.
91. Belleli R, Fisch R, Renard D, Woehling H, Gsteiger S. Assessing switchability for biosimilar products: modelling approaches applied to children’s growth. Pharm Stat. 2015;14(4):341–9.
92. Romer T, Zabransky M, Walczak M, Szalecki M, Balser S. Effect of switching recombinant human growth hormone: comparative analysis of phase 3 clinical data. Biol Ther. 2011;1:5.
93. Engert A, Griskevicius L, Zyuzgin Y, Lubenau H, del Giglio A. XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. Leuk Lymphoma. 2009;50(3):374–9.
94. Gatzemeier U, Ciuleanu T, Dediu M, Ganea-Motan E, Lubenau H, Del Giglio A. XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy. J Thorac Oncol. 2009;4(6):736–40.
95. Krendyukov A, Harbeck N, Gascon P, Gattu S, Li Y, Blackwell KL. Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim for the prevention of severe neutropenia, in patients with breast cancer receiving myelosuppressive chemotherapy. J Clin Oncol. 2017;35:abstr10116 (abstract).
96. Gooderham M, Spelman L, Kaliaperumal A, Costanzo A, Narbutt J, Zhang N, et al. Single transition from adalimumab to ABP 501: evaluation of immunogenicity in a phase 3 study in subjects with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;74(5):AB275 (abstract).
97. Papp K, Bachelez H, Costanzo A, Foley P, Gooderham M, Kaur P, et al. Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: a randomized, double-blind, multicenter, phase III study. J Am Acad Dermatol. 2017;76(6):1093–102.
98. Weinblatt M, Baranauskaite A, Niebrzydowski J, Dokoupilova E, Zielinska A, Sitek-Ziolkowska K, et al. Sustained efficacy and comparable safety and immunogenicity after transition to SB5 (an adalimumab biosimilar) vs continuation of the adalimumab reference product in patients with rheumatoid arthritis: results of phase III study EUCLAR 2016; 8–11 June 2016; London UK (abstract FRI0161). Arthritis Rheumatol. 2016;68(suppl 10):abstract 604.
99. Nasonov E, Mazurov V, Plaksina T, Nesmeyanova O, Knyazeva L, Eremeeva A, et al. Interchangeability of innovator rituximab and its biosimilar: results from international controlled comparative 1-year study in patients with active rheumatoid arthritis. Arthritis Rheumatol. 2016;68:2046–7.
100. Roy PS, John S, Karankal S, Kannan S, Pawaskar P, Gawande J, et al. Comparison of the efficacy and safety of rituximab (Mabthera) and its biosimilar (Reditux) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: a retrospective analysis. Indian J Med Paediatr Oncol. 2013;34(4):292–8.
101. ®) to SB4. Arthritis Rheumatol. 2016;68(suppl 10):789–90 (abstract).
102. Emery P, Vencovsky J, Sylwestrzak P, Leszczynski P, Porawska W, Stasiuk B, et al. Long-term safety and efficacy of SB4 (etanercept biosimilar) in patients with rheumatoid arthritis: comparison between continuing SB4 and switching from etanercept reference product to SB4. Ann Rheum Dis. 2016;75(Suppl 2):236 (abstract).
103. Griffiths CEM, Thaci D, Gerdes S, Arenberger P, Pulka G, Kingo K, et al. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol. 2017;176(4):928–38.
104. ® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: a phase 3 open-label follow-up to main study. Reprod Biol Endocrinol. 2016;14(1):31.
105. Glintborg B, Kringelbach T, Hogdall E, Sorensen IJ, Jensen DV, Loft AG, et al. Non-medical switch from originator to biosimilar infliximab among patients with inflammatory rheumatic disease—impact on S-infliximab and antidrug-antibodies. Results from the National Danish Rheumatologic Biobank and the Danbio Registry. Ann Rheum Dis. 2016;75(Suppl 2):224 (abstract).
106. Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305(14):1460–8.
107. Pascual-Salcedo D, Plasencia C, Ramiro S, Nuno L, Bonilla G, Nagore D, et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford). 2011;50(8):1445–52.
108. Thomas SS, Borazan N, Barroso N, Duan L, Taroumian S, Kretzmann B, et al. Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. A systematic review and meta-analysis. BioDrugs. 2015;29(4):241–58.
109. Dowlat HA, Kuhlmann MK, Khatami H, Ampudia-Blasco FJ. Interchangeability among reference insulin analogues and their biosimilars: regulatory framework, study design and clinical implications. Diabetes Obes Metab. 2016;18(8):737–46.
110. Goll GL, Olsen IC, Jorgensen KK, Lorentzen M, Bolstad N, Haavardsholm EA, et al. Biosimilar infliximab (CT-P13) is not inferior to originator infliximab: results from a 52-week randomized switch trial in Norway Arthritis Rheumatol. 2016;68 (suppl 10) abstract 19L.
111. Gautam A. Market watch: strategies for biosimilars in emerging markets. Nat Rev Drug Discov. 2017;16(8):520–1.
112. Marciano I, Ingrasciotta Y, Giorgianni F, Bolcato J, Chinellato A, Pirolo R, et al. How did the introduction of biosimilar filgrastim influence the prescribing pattern of granulocyte colony-stimulating factors? Results from a multicentre, population-based study, from five Italian centres in the years 2009–2014. BioDrugs. 2016;30(4):295–306.
113. Ingrasciotta Y, Giorgianni F, Bolcato J, Chinellato A, Pirolo R, Tari DU, et al. How much are biosimilars used in clinical practice? A retrospective Italian population-based study of erythropoiesis-stimulating agents in the years 2009–2013. BioDrugs. 2015;29(4):275–84.
114. Ruiz-Arguello MB, Maguregui A, Ruiz Del Agua A, Pascual-Salcedo D, Martinez-Feito A, Jurado T, et al. Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars. Ann Rheum Dis. 2016;75(9):1693–6.
115. Li E, Ramanan S, Green L. Pharmacist substitution of biological products: issues and considerations. J Manag Care Spec Pharm. 2015;21(7):532–9.
116. DePalma A. Glycosylation affirmed as quality metric. GEN Select. 2014;34(13):5263.
117. Chung S, Quarmby V, Gao X, Ying Y, Lin L, Reed C, et al. Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcgamma receptor binding and antibody-dependent cell-mediated cytotoxicity activities. MAbs. 2012;4(3):326–40.
118. Kanda Y, Yamada T, Mori K, Okazaki A, Inoue M, Kitajima-Miyama K, et al. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology. 2007;17(1):104–18.
119. Houde D, Peng Y, Berkowitz SA, Engen JR. Post-translational modifications differentially affect IgG1 conformation and receptor binding. Mol Cell Proteomics. 2010;9(8):1716–28.
120. Yu M, Brown D, Reed C, Chung S, Lutman J, Stefanich E, et al. Production, characterization, and pharmacokinetic properties of antibodies with N-linked mannose-5 glycans. MAbs. 2012;4(4):475–87.
121. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant. 2001;16(Suppl 3):3–13.
122. Murakami M, Kiuchi T, Nishihara M, Tezuka K, Okamoto R, Izumi M, et al. Chemical synthesis of erythropoietin glycoforms for insights into the relationship between glycosylation pattern and bioactivity. Sci Adv. 2016;2(1):e1500678.
123. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med. 2008;358(11):1109–17.
124. Burska AN, Hunt L, Boissinot M, Strollo R, Ryan BJ, Vital E, et al. Autoantibodies to posttranslational modifications in rheumatoid arthritis. Mediators Inflamm. 2014;492873(10):492873.
125. Zhong X, Wright JF. Biological insights into therapeutic protein modifications throughout trafficking and their biopharmaceutical applications. Int J Cell Biol. 2013;273086(10):273086.
126. Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis. 2013;72(2):165–78.
127. Beck A, Reichert JM. Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry. MAbs. 2013;5(5):621–3.
128. Magnenat L, Palmese A, Fremaux C, D’Amici F, Terlizzese M, Rossi M, et al. Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira(R). MAbs. 2017;9(1):127–39.
129. Jefferis R, Lefranc MP. Human immunoglobulin allotypes: possible implications for immunogenicity. MAbs. 2009;1(4):332–8.
130. Locatelli F, Del Vecchio L, Pozzoni P. Pure red-cell aplasia “epidemic”—mystery completely revealed? Perit Dial Int. 2007;27(2):S303–7.
131. US Food and Drug Administration. Nonproprietary naming of biological products: guidance for industry. 2017. https://www.fda.gov/downloads/drugs/guidances/ucm459987.pdf. Accessed 17 Oct 2017.
132. Grampp G, Felix T. Pharmacovigilance considerations for biosimilars in the USA. BioDrugs. 2015;29(5):309–21.
133. Vermeer NS, Straus SM, Mantel-Teeuwisse AK, Domergue F, Egberts TC, Leufkens HG, et al. Traceability of biopharmaceuticals in spontaneous reporting systems: a cross-sectional study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance databases. Drug Saf. 2013;36(8):617–25.
134. Ekelund M, Bidad C, Gomez R. To the editor; a commentary on “Switching from originator to biosimilar human growth hormone using a dialogue teamwork: single-center experience from Sweden”. Biol Ther. 2014;4(1–2):69–71.